Literature DB >> 20018759

miR-221 overexpression contributes to liver tumorigenesis.

Pascal Pineau1, Stefano Volinia, Katherine McJunkin, Agnès Marchio, Carlo Battiston, Benoît Terris, Vincenzo Mazzaferro, Scott W Lowe, Carlo M Croce, Anne Dejean.   

Abstract

MicroRNA (miRNAs) are negative regulators of gene expression and can function as tumor suppressors or oncogenes. Expression patterns of miRNAs and their role in the pathogenesis of hepatocellular carcinoma (HCC) are still poorly understood. We profiled miRNA expression in tissue samples (104 HCC, 90 adjacent cirrhotic livers, 21 normal livers) as well as in 35 HCC cell lines. A set of 12 miRNAs (including miR-21, miR-221/222, miR-34a, miR-519a, miR-93, miR-96, and let-7c) was linked to disease progression from normal liver through cirrhosis to full-blown HCC. miR-221/222, the most up-regulated miRNAs in tumor samples, are shown to target the CDK inhibitor p27 and to enhance cell growth in vitro. Conversely, these activities can be efficiently inhibited by an antagomiR specific for miR-221. In addition, we show, using a mouse model of liver cancer, that miR-221 overexpression stimulates growth of tumorigenic murine hepatic progenitor cells. Finally, we identified DNA damage-inducible transcript 4 (DDIT4), a modulator of mTOR pathway, as a bona fide target of miR-221. Taken together, these data reveal an important contribution for miR-221 in hepatocarcinogenesis and suggest a role for DDIT4 dysregulation in this process. Thus, the use of synthetic inhibitors of miR-221 may prove to be a promising approach to liver cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20018759      PMCID: PMC2806773          DOI: 10.1073/pnas.0907904107

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.

Authors:  Y Murakami; T Yasuda; K Saigo; T Urashima; H Toyoda; T Okanoue; K Shimotohno
Journal:  Oncogene       Date:  2006-04-20       Impact factor: 9.867

2.  MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleukemic cell growth via kit receptor down-modulation.

Authors:  Nadia Felli; Laura Fontana; Elvira Pelosi; Rosanna Botta; Desirée Bonci; Francesco Facchiano; Francesca Liuzzi; Valentina Lulli; Ornella Morsilli; Simona Santoro; Mauro Valtieri; George Adrian Calin; Chang-Gong Liu; Antonio Sorrentino; Carlo M Croce; Cesare Peschle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-05       Impact factor: 11.205

3.  The role of microRNA genes in papillary thyroid carcinoma.

Authors:  Huiling He; Krystian Jazdzewski; Wei Li; Sandya Liyanarachchi; Rebecca Nagy; Stefano Volinia; George A Calin; Chang-Gong Liu; Kaarle Franssila; Saul Suster; Richard T Kloos; Carlo M Croce; Albert de la Chapelle
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-19       Impact factor: 11.205

4.  Probing tumor phenotypes using stable and regulated synthetic microRNA precursors.

Authors:  Ross A Dickins; Michael T Hemann; Jack T Zilfou; David R Simpson; Ingrid Ibarra; Gregory J Hannon; Scott W Lowe
Journal:  Nat Genet       Date:  2005-10-02       Impact factor: 38.330

Review 5.  Primary liver cancer: worldwide incidence and trends.

Authors:  F Xavier Bosch; Josepa Ribes; Mireia Díaz; Ramon Cléries
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

6.  Homozygous deletion scanning in hepatobiliary tumor cell lines reveals alternative pathways for liver carcinogenesis.

Authors:  Pascal Pineau; Agnès Marchio; Seishi Nagamori; Shuichi Seki; Pierre Tiollais; Anne Dejean
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

Review 7.  Epidemiology and natural history of hepatocellular carcinoma.

Authors:  Katherine A McGlynn; W Thomas London
Journal:  Best Pract Res Clin Gastroenterol       Date:  2005-02       Impact factor: 3.043

8.  Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Won Kim; Seung Oe Lim; Jong-Seo Kim; Young Hee Ryu; Ji-Yeon Byeon; Hie-Joon Kim; Yong-Il Kim; Jin Seok Heo; Young Min Park; Guhung Jung
Journal:  Clin Cancer Res       Date:  2003-11-15       Impact factor: 12.531

9.  Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach.

Authors:  Lars Zender; Mona S Spector; Wen Xue; Peer Flemming; Carlos Cordon-Cardo; John Silke; Sheung-Tat Fan; John M Luk; Michael Wigler; Gregory J Hannon; David Mu; Robert Lucito; Scott Powers; Scott W Lowe
Journal:  Cell       Date:  2006-06-30       Impact factor: 41.582

10.  A microRNA expression signature of human solid tumors defines cancer gene targets.

Authors:  Stefano Volinia; George A Calin; Chang-Gong Liu; Stefan Ambs; Amelia Cimmino; Fabio Petrocca; Rosa Visone; Marilena Iorio; Claudia Roldo; Manuela Ferracin; Robyn L Prueitt; Nozumu Yanaihara; Giovanni Lanza; Aldo Scarpa; Andrea Vecchione; Massimo Negrini; Curtis C Harris; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-03       Impact factor: 11.205

View more
  339 in total

1.  Negative feedback of miR-29 family TET1 involves in hepatocellular cancer.

Authors:  Li Li Lin; Wei Wang; ZhaoYang Hu; Li Wen Wang; Jing Chang; HanGuang Qian
Journal:  Med Oncol       Date:  2014-11-04       Impact factor: 3.064

Review 2.  microRNAs: tiny RNA molecules, huge driving forces to move the cell.

Authors:  Shenglin Huang; Xianghuo He
Journal:  Protein Cell       Date:  2010-11-09       Impact factor: 14.870

Review 3.  Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.

Authors:  Igor P Pogribny; Ivan Rusyn
Journal:  Cancer Lett       Date:  2012-02-02       Impact factor: 8.679

Review 4.  Epigenetic regulation of cancer stem cells in liver cancer: current concepts and clinical implications.

Authors:  J U Marquardt; V M Factor; S S Thorgeirsson
Journal:  J Hepatol       Date:  2010-05-31       Impact factor: 25.083

5.  Function and clinical potential of microRNAs in hepatocellular carcinoma.

Authors:  Lijuan Wang; Yongfang Yue; Xian Wang; Hongchuan Jin
Journal:  Oncol Lett       Date:  2015-09-29       Impact factor: 2.967

Review 6.  MicroRNAs as therapeutic targets in human cancers.

Authors:  Maitri Y Shah; George A Calin
Journal:  Wiley Interdiscip Rev RNA       Date:  2014-03-28       Impact factor: 9.957

Review 7.  Epigenetics of hepatocellular carcinoma: role of microRNA.

Authors:  Sharad Khare; Qiong Zhang; Jamal A Ibdah
Journal:  World J Gastroenterol       Date:  2013-09-07       Impact factor: 5.742

8.  Identification of microRNAs specifically expressed in hepatitis C virus-associated hepatocellular carcinoma.

Authors:  Giacomo Diaz; Marta Melis; Ashley Tice; David E Kleiner; Lopa Mishra; Fausto Zamboni; Patrizia Farci
Journal:  Int J Cancer       Date:  2013-03-16       Impact factor: 7.396

9.  Circulating microRNAs (cmiRNAs) as novel potential biomarkers for hepatocellular carcinoma.

Authors:  J Qi; J Wang; H Katayama; S Sen; S M Liu
Journal:  Neoplasma       Date:  2013       Impact factor: 2.575

10.  MicroRNAs 221 and 222 regulate the undifferentiated state in mammalian male germ cells.

Authors:  Qi-En Yang; Karen E Racicot; Amy V Kaucher; Melissa J Oatley; Jon M Oatley
Journal:  Development       Date:  2012-12-05       Impact factor: 6.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.